Germline variants associated with immunotherapy-related adverse events

Stefan Groha(Dana-Farber Cancer Institute), Alexander Gusev(Dana-Farber Cancer Institute), Tanya E. Keenan(Massachusetts General Hospital), Leyre Zubiri(Massachusetts General Hospital), Talal El Zarif(Yale University), Ziad Bakouny(Dana-Farber Cancer Institute), Biagio Ricciuti(Harvard University), Kerry L. Reynolds(Massachusetts General Hospital), Eliezer M. Van Allen(Dana-Farber Cancer Institute), Alexandra–Chloé Villani(Broad Institute), Toni K. Choueiri(Harvard University), Pier Vitale Nuzzo(Dana-Farber Cancer Institute), Yevgeniy R. Semenov(Harvard University), Kenneth L. Kehl(Dana-Farber Cancer Institute), Wenxin Xu(Dana-Farber Cancer Institute), Elio Adib(Dana-Farber Brigham Cancer Center), David A. Braun(Yale Cancer Center), Michael P. Manos(Harvard University), Amin H. Nassar(Brigham and Women's Hospital), Vivek Naranbhai(Centre for Human Genetics), Osama E. Rahma(Dana-Farber/Harvard Cancer Center), Sachet A. Shukla(The University of Texas MD Anderson Cancer Center), Joao V. Alessi(Hospital Sírio-Libanês), Mark M. Awad(Memorial Sloan Kettering Cancer Center), Matthew L. Freedman(Brigham and Women's Hospital), Andrew Schmidt(Dana-Farber Cancer Institute), Deborah Schrag(Dana-Farber Brigham Cancer Center), Zia Khan, Sarah Abou Alaiwi(Yale New Haven Hospital), Christian M. Hammer, Chris Labaki(Beth Israel Deaconess Medical Center)
medRxiv
April 12, 2022
Cited by 0


Related Papers